59,302 Shares in STAAR Surgical Company $STAA Purchased by Quantinno Capital Management LP

Posted by George Bondi on Aug 16th, 2026

Quantinno Capital Management LP purchased a new position in shares of STAAR Surgical Company (NASDAQ:STAA – Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 59,302 shares of the medical instruments supplier’s stock, valued at approximately $1,109,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in STAAR Surgical by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier’s stock valued at $518,000 after acquiring an additional 1,267 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of STAAR Surgical by 33.4% during the first quarter. Goldman Sachs Group Inc. now owns 544,843 shares of the medical instruments supplier’s stock worth $9,606,000 after purchasing an additional 136,390 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of STAAR Surgical by 11.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,347 shares of the medical instruments supplier’s stock worth $2,175,000 after purchasing an additional 12,841 shares in the last quarter. Creative Planning grew its stake in shares of STAAR Surgical by 19.9% during the second quarter. Creative Planning now owns 15,695 shares of the medical instruments supplier’s stock valued at $263,000 after purchasing an additional 2,606 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of STAAR Surgical by 183.2% during the second quarter. JPMorgan Chase & Co. now owns 153,371 shares of the medical instruments supplier’s stock valued at $2,574,000 after purchasing an additional 99,218 shares during the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Price Performance

Shares of NASDAQ:STAA opened at $26.18 on Friday. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of 374.05 and a beta of 1.26. The company has a 50 day moving average of $26.81 and a 200-day moving average of $24.14. STAAR Surgical Company has a one year low of $15.59 and a one year high of $35.87.

STAAR Surgical (NASDAQ:STAA – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The medical instruments supplier reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.06). STAAR Surgical had a net margin of 1.13% and a return on equity of 9.05%. The business had revenue of $93.53 million during the quarter, compared to analyst estimates of $90.60 million. During the same quarter in the prior year, the company earned ($0.34) earnings per share. The company’s quarterly revenue was up 111.1% on a year-over-year basis. Equities research analysts anticipate that STAAR Surgical Company will post 0.13 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on STAA. Jefferies Financial Group restated a “hold” rating and issued a $28.00 price objective on shares of STAAR Surgical in a research report on Thursday. Weiss Ratings raised STAAR Surgical from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Thursday. Wall Street Zen downgraded STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. UBS Group cut their price target on STAAR Surgical from $20.00 to $19.00 and set a “sell” rating on the stock in a research note on Thursday. Finally, Stifel Nicolaus raised their price target on STAAR Surgical from $18.00 to $31.00 and gave the company a “hold” rating in a report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, seven have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $27.80.

View Our Latest Stock Report on STAA

STAAR Surgical Company Profile

(Free Report)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.